TGIF2 and prostate neoplasm: Importantly, miR-181a is identified as an oncogenic role in prostate cancer cells and prostate tumor samples, and miR-181a promotes epithelial to mesenchymal transition of prostate cancer cells by targeting TGIF2 [18].